Schad H, Heimisch W, Barankay A, Hesse S, Mendler N
Klinik für Herz- und Gefässchirurgie, Deutsches Herzzentrum München, Federal Republic of Germany.
Res Exp Med (Berl). 1992;192(5):355-65. doi: 10.1007/BF02576292.
The 5-HT-2 antagonist ketanserin (KAS) has been successfully used to treat acute hypertension in coronary bypass surgery. The present study was performed to investigate the effect of KAS on ischaemic myocardium. In 11 anaesthetized (piritramide) dogs, systolic contraction (sdL) and end-diastolic length (edL) of myocardium supplied by the left descending coronary artery (LAD) and the left circumflex coronary artery (LCX) were measured by sonomicrometry simultaneously with aortic pressure (AoP), left ventricular dP/dtmax and end-diastolic pressure (LVedP), heart rate (HR), stroke volume, and LAD flow (QLAD). Regional ischaemia to decrease sdLLAD (-48%) was achieved by LAD stenosis (QLAD -47%). Concomitantly, edLLAD increased by 8%. However, the other variables did not change. Then KAS was given i.v. (0.15 + 0.15 + 0.30 + 0.6 mg/kg) at 15-min intervals. Following KAS, prestenotic sdLLAD recovered in a dose-dependent manner. LVedP and edLLAD decreased, sdLLCX increased, and the other variables were not affected. This functional recovery of ischaemic myocardium was attenuated by pretreatment with metoprolol (MET, 1 mg/kg) prior to LAD stenosis. The ischaemic area was not irreversibly damaged, however, as proven by the recovery of prestenotic sdLLAD values after release of the stenosis. The improved systolic shortening of ischaemic myocardium following KAS did not result from restored QLAD due to post-stenotic vasodilation or break up of platelet aggregates (QLAD did not increase) or from reduced afterload (AoP did not decrease). Obviously, it was mediated by beta-1-receptors, as shown by the attenuation of the beneficial effect of KAS by pretreatment with MET.
5-羟色胺-2拮抗剂酮色林(KAS)已成功用于治疗冠状动脉搭桥手术中的急性高血压。本研究旨在探讨KAS对缺血心肌的影响。在11只麻醉(匹利卡明)犬中,通过超声测量法同时测量左冠状动脉前降支(LAD)和左旋支冠状动脉(LCX)供血心肌的收缩期缩短(sdL)和舒张末期长度(edL),以及主动脉压(AoP)、左心室dP/dtmax和舒张末期压力(LVedP)、心率(HR)、每搏输出量和LAD血流量(QLAD)。通过LAD狭窄(QLAD降低47%)实现局部缺血,使sdLLAD降低48%。与此同时,edLLAD增加了8%。然而,其他变量没有变化。然后每隔15分钟静脉注射KAS(0.15 + 0.15 + 0.30 + 0.6 mg/kg)。注射KAS后,狭窄前的sdLLAD以剂量依赖的方式恢复。LVedP和edLLAD降低,sdLLCX增加,其他变量未受影响。在LAD狭窄前用美托洛尔(MET,1 mg/kg)预处理可减弱缺血心肌的这种功能恢复。然而,缺血区域并未受到不可逆转的损伤,因为狭窄解除后狭窄前sdLLAD值的恢复证明了这一点。KAS后缺血心肌收缩期缩短的改善并非由于狭窄后血管舒张或血小板聚集物解体导致的QLAD恢复(QLAD未增加),也不是由于后负荷降低(AoP未降低)。显然,它是由β-1受体介导的,如用MET预处理减弱了KAS的有益作用所示。